Skip to main content
Menu

Posts tagged with "Diabetes and Obesity"

  • Cardiovascular Disease

    Tricor’s Troubles

    It’s easy to lose sight of what a drug is supposed to do. Many conditions come on so slowly that we have to use blood chemistry or other markers to see the progress of therapy in a realistic time. And over time, that blood marker can get confused with the disease itself. To pick one… Read More
  • Biological News

    Your Own Personal Bacteria

    There’s a report in Nature on the bacteria found in the human gut that’s getting a lot of press today (especially for a paper about, well, bacteria in the human gut). A team at the Beijing Genomics Institute, with many collaborators, has done a large shotgun sequencing effort on gut flora and identified perhaps one… Read More
  • Cardiovascular Disease

    Steve Nissen’s Meeting with GSK

    Well, this is interesting. Back when Steve Nissen was about to publish his meta-analysis on the safety of Avandia (rosigiltazone), he met with several GlaxoSmithKline executives before the paper came out. At the time, GSK was waiting on data from the RECORD study, which was trying to address the same problem (unconvincingly, for most observers… Read More
  • Diabetes and Obesity

    Avandia: Off the Market or Not?

    The Senate report that leaked on Avandia (rosiglitazone) over the weekend has made plenty of headlines. It quotes an internal FDA report that recommends flatly that the drug be removed from the market, since its beneficial effects can be achieved by use of the competing PPAR drug Actos (pioglitazone), which doesn’t seem to have the… Read More
  • Aging and Lifespan

    Sirtuin Scenarios

    So, after reading what Pfizer has to say about Sirtris (and by extension, about GlaxoSmithKline’s heavy investment in them), let’s go over the possibilities. What happened, and what’s going on? We’ll start out with the first branch point: either Pfizer (and Amgen) are right that there’s trouble with the Sirtris assays… Read More
  • Diabetes and Obesity

    Gaining and Losing and Discovering and Selling

    Obesity has been one of those therapeutic areas that drug companies can’t quite stay away from. A glance at the potential patient ranks, expanding in every sense of the word, is enough to explain why. But as I’ve detailed here in the past, finding an effective obesity drug is not easy, for many good reasons. Read More
  • Biological News

    MAGL: A New Cancer Target

    I do enjoy some good chemical biology, and the latest Cell has another good example from the Cravatt group at Scripps (working with a team at Brigham and Women’s Hospital over here on this coast). What they’ve done is profile various types of tumor cells using an activity-based probe to search for changes in serine… Read More
  • Diabetes and Obesity

    Obesity: Hope Springs Eternal (Summer 2009 Version)

    Some very interesting papers from the obesity research field have been published in the last few months. There have been a number of these over the years, and (as is widely apparent), none of them have quite lived up to their initial promise. This latest mechanism has been written up by both academic groups and… Read More
  • Diabetes and Obesity

    Obesity Shows Up in the Death Rate? Right?

    Here’s an interesting post at Chemiotics (a new addition to the blogroll): Something is Wrong With the Model . . . The Center for Disease Control released new data for 2007 (based on 90% of all USA death certificiates) showing that mortality rates dropped again (by over 2%) to 760/100,000 population. It’s been dropping for… Read More
  • Business and Markets

    Arena, Lorcaserin, and the FDA

    I’ve been getting a lot of objections to my opinion on Arena’s obesity candidate lorcaserin. Specifically, the first level of the dispute seems to be whether or not the recent clinical trial results met the FDA’s criteria for efficacy or not. So, let’s look at the details. Here’s how Arena press-released the results of the… Read More
...8910...